Jefferies analyst Alok Dalal downgraded Dr. Reddy’s to Underperform from Buy with an unchanged price target of $61.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RDY:
- Dr. Reddy’s price target raised to $80 from $75 at Barclays
- Dr. Reddy’s downgraded to Underperform from Buy at Jefferies
- Journey Medical submits NDA to FDA for DFD-29
- Coya Therapeutics’ CEO gives update, sufficient cash for COYA 302 Phase 2 trial
- Dr. Reddy’s partners with Coya on commercialization for COYA 302 for ALS